Scientists see progress in prostate cancer tests

	Tweet

Two companies have developed genetic tests that eventually could help doctors better predict which prostate cancer patients have serious cases that need aggressive treatment, U.S. researchers reported on Wednesday.

One test, developed by San Diego-based Illumina Inc., was designed to help physicians tell which patients considered at medium risk will have their cancer recur after the prostate is removed. Those patients typically have a score of 6 or 7 on the 10-point Gleason scale that is among the standard tests for prostate cancer.

Researchers used the Illumina test to analyze prostate cancer tissue samples for 16 genes and studied how patients fared. They said they could use the information to give patients a score indicating whether they were likely to experience a recurrence of cancer within the next five years.

If confirmed in future studies, “this information could be used to make the next leap as to what (treatment) a patient should or should not have,” said Dr. Tracy Downs, a urologic oncologist at the University of California at San Diego.

Another test developed by Berlin-based Epigenomics AG detected a gene called PITX2 and its “methylation,” a chemical alteration that controls how active a gene is. The PITX2 gene is thought to play a role in regulating hormones, which can fuel cancer growth.

Men whose tissue samples tested positive on the Epigenomics test were three times more likely to experience cancer recurrence after having their prostate removed, researchers said.

“Those are the people that are really possibly good candidates for early (post-surgical) therapy,” said Susan Cottrell, a senior scientist at Epigenomics’s Seattle-based U.S. unit.

The company plans to seek Food and Drug Administration approval of the test if its effectiveness is confirmed in a larger study, Cottrell said. The test could be available for use in patients “in another couple years,” she added.

Findings on both tests were released at a meeting of the American Association for Cancer Research.

Neither test was designed to replace the Gleason score or the PSA test that doctors typically use to determine the severity of prostate cancer, the researchers said.

Prostate cancer is the most common cancer in U.S. men. It is diagnosed in 232,000 men every year and kills up to 30,000 of them. Worldwide, 221,000 men die from prostate cancer each year.

RELATED STORIES:
Hormone Therapy for Prostate Cancer Patients With Heart Conditions Linked to Increased Death Risk   Higher vitamin K intake tied to lower cancer risks   Prostate cancer therapy linked to bone loss   Obesity raises risk of prostate cancer recurrence   Older men may not need prostate cancer screening   What is the role of focal therapy in low-risk prostate cancer?   Variances in patterns of care for patients with prostate cancer failing primary therapy   Height linked to risk of prostate cancer development and progression   Single men may forgo retreatment of prostate cancer   MRI findings help forecast prostate cancer prognosis   Genetic factors implicated in survival gap for breast, ovarian or prostate cancer   Prostate cancer therapy linked to increased risk of heart disease death   Diet may make a difference in prostate cancer   No risk seen from delaying prostate cancer surgery   Novel drug selectively kills prostate cancer cells   Louis Gossett Jr. fighting prostate cancer   Many prostate cancer patients receive improper or ‘mismatched’ therapies   Excessive Multivitamin Use May Raise Risk for Prostate Cancer   Men Can Take Their Time to Decide on Prostate Cancer Treatment   Hopkins Prostate Cancer Experts Available   Severe Form of “Enlarged Prostate” Disease Discovered   Prostate cancer therapy not tied to bladder cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]